Therefore, the clinical application of miR-34a mimics or inhibitors targeting LOXL3 may offer potential protective effects for CRC patients undergoing desflurane anesthesia (Ren et al., 2021). The gene discussed is LOXL3; the disease is colorectal carcinoma.